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1. Introduction
Attention Deficit and Hyperactivity Disorder (ADHD) comprises a disorder which is charac‐
terized with inattention, hyperactivity and impulsivity, seen in 3-7% of school-age children
Boys are two to nine times more often affected than girls [1]. Twin, adoption, and molecular
genetic studies show ADHD to be highly heritable. Evidence from animal and human studies
implicates the dysregulation of frontal-subcortical-cerebellar catecholaminergic circuits in the
pathophysiology of ADHD. Imaging studies suggest that abnormalities of the dopaminergic
and adrenergic transmitter systems lead to impaired neurotransmission [2]
The  main  course  of  ADHD  is  a  persistent  pattern  of  inattention  and/or  hyperactivity-
impulsivity  that  may be  seen more  frequently  and/or  severely  compared to  individuals
with  the  same  level  of  development.  Its  pathophysiology  appears  to  involve  different
alterations in dopaminergic  and noradrenergic  pathways related to  the control  of  atten‐
tion and impulsivity [1,3,4].
ADHD is associated with important deterioration at numerous fields such as developmental,
cognitive, emotional, social and academical, and also associated with personal time for parents
because of affecting several health risks and academic performance. Deterioration in these
fields based on basic sypmtoms of ADHD: hyperactivity, inattention and impulsivity [5]. In
case of ADHD, as a result of inadequacies any time in the life of the child, reduction in self-
confidence, misery, failure and thus reduced quality of life; deterioration of interpersonal and
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intra-family relations, being affected adversely of psychological well-being could be seen.
Therefore, it is reported that “psychosocial dimension” gains importance gradually besides
clinical parameters in multidimensional monitoring of disease and adequacy and inadequacy
in this dimension could be explained with “life quality” concept [6]. Because of difficulties in
academical, social and emotional fields, the effects of deterioration over life quality came into
discussion in the context of the recent literature [7,8,9]. This level of interest is not surprising
due to the complexity of the relationships; QoL(Quality of life) is not only influenced by the
disorder itself, but also by many proximal (i.e. family, friendship) and distal (socioeconomic
and cultural) factors. In addition to its core symptoms of attention deficit, hyperactivity and
impulsivity, ADHD is associated with numerous developmental, cognitive, emotional, social
and academic impairments [10,11].
The psychostimulants (e.g., methylphenidate) are considered the first-line of therapy for
ADHD, relieving symptoms by increasing intrasynaptic dopamine, norepinephrine, and
serotonin [12]. Nevertheless, some patients fail to respond to stimulants or are unable to
tolerate them, and the stimulants such as methylphenidate are contraindicated for some
children and adolescents including those with Tourette’s disorder. Nonstimulant agents used
in ADHD include tricyclic antidepressants, bupropion, clonidine, guanfacine, selective
serotonin reuptake inhibitors, and newer atypical antidepressants [13,14]. But their current use
is limited, because these agents do not improve impulsive behavior and cognitive impairments
and also they have serious adverse effects [15].
On the other hand, atomoxetine, a highly selective inhibitor of the noradrenergic transporter,
is the first non-psychostimulant agent approved by the Food and Drug Administration (FDA)
for ADHD. Compared to its effect on the norepinephrine transporter, atomoxetine has very
little affinity for the dopamine or serotonin transpoter. As a result of the central role of CYP2D6
in metabolism of atomoxetine, the activity of this enzyme plays a significant role in its
pharmachokinetics. The majority of people ([90%), who metabolise atomoxetine and other
CYP2D6 substrates relatively rapidly, are designed as CYP2D6 extensive metaboliser. Its
efficacy in children with ADHD has been demonstrated in three double-blind, placebo-
controlled trials [16].
Commonly used drugs for ADHD are shown in table 1.
Drug Dosage Dosage range Time of Maximum plasmaconcentraiton (hour) FDA approval year
Concerta 18,27,36,54,72 18-72 8 2000
Metadate CD 10,20,30 20-60 5 2001
Ritalin LA 10,20,30,40 20-60 5 2002
Adderall XR 10,20,30 10-40 1-4 2001
Ritalin 5,10,20 10-60 0.3-4 2000
Atomoksetin 10,18,25,40,60 10-60 1-2,3-4 2002
Table 1. Commonly used drugs for ADHD
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Consequently, methylphenidate for stimulant group and atomoxetine for nonstimulant group
are in primer use for ADHD treatment. The use of these medications becomes widespread
gradually. It is reported that both medications are effective on treatment of ADHD’s basic
symptoms in children and adolescents. Thus, significant improvement could be seen in life
quality [9,17,18]. When comparing with normal population, difficulties in academical, social
and emotional fields could be developed more frequently.
The side effects on weight and height of these medications which are used considerably in
child psychiatry are in discussion over a long time. Although a few studies defend inefficiency
over weight and height, some studies show arrest in height development and shortness in
ultimate height [19]. Current studies in this content on children and adolescents are subjects
of only a few studies specially in our country [20].
In our study, we aimed to compare the effect of long acting methylphenidatefor and/or
atomoxetine usage due to ADHD, weight-height measurements, and comparison of life quality
between children and adolescents, and healthy population.
2. Material and methods
This study was conducted in Department of Child and Adolescent Pscyhiatry, Erciyes
University Faculty of Medicine in the period from September 2011 to May 2012. Study
population consists of 52 patients with ADHD based on DSM-IV and these patients were
pharmacologically treated for at least 12 months and sypmtom severity is consistent with
Scanning and Evaluation Scale based on DSM-IV for Behavioral Disorders in Children and
Adolescents. Coexisting psychiatric disorders were accepted as exclusion criteria. Children
with no previous history of psychopharmalogical treatment except ADHD and simultaneously
no previous history of epilepsy and other medical disease was examined. Control group was
selected randomly between patients of social pediatric clinical and specified as 25 healthy
children in physical and psychological way. Smilarity between control and patient group from
the point of gender and age avaragewas noticed. Parents of children with ADHD filled
sociodemographic data form, The Pediatric Quality of Life Inventory(PedsQL), Atilla Turgay
Scanning and Evaluation Scale based on DSM-IV for Behavioral Disorders in Children and
Adolescents. Weight and height measurements were performed by our nurse specialist.
Parents of control group also filled the same tests. Parents of both group signed informed
consent and ethics committee approval was obtained.
3. Scales used in this study
The Pediatric Quality of Life Inventory(PedsQL): Developed for psychosocial and physcial life
quality measurement of children and adolescent between 2-18 age interval by Varni and et all.
and adapted into Turkish for 8-18 age interval was carried out by Çakın Memik et al. [21,22].
It is obtained that Cronbach Alfa coefficients vary between 0.80 and 0.88. PedsQL between the
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ages of 8-18 children / adolescents, there are forms for both self-report and parent and consists
of 23 articles. The scale of physical health, emotional functioning, social functioning, and school
functioning challenged areas. Scoring, scale total score (CAP), physical health score (FSTP),
emotional, social and school functioning scores evaluating the substance of the calculation of
the total score of psychosocial health (PSTP) to be carried out in three areas. This is the last
month of children and adolescents with the scale in question. Substances "never", "rarely",
"sometimes", "often" or "always" in the form of, and in turn responded, 100, 75, 50, 25, 0 points
are given. Points total score is obtained by dividing the number of items collected and
replenished. As a result the higher the PedsQL total score, the better the perceived health-
related quality of life [20].
Thus fields of physical health, emotional functioning, social functioning and shcool function‐
ing as features of well-being, identified by WHO, was examined.
Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale:
This scale was developed by Turgay [23], based on DSM-IV diagnosis criteria. This scale
consists of 41 questions; 9 of them for attention deficit, 9 of them for mobility and impulsivity,
8 of them for comorbid oppositional defiant disorder (ODD), and 15 of them for behavioral
disorder. Each question has 4 choices: 0 for strongly disagree, 1 for somewhat, 2 for agree, 3
for strongly agree. For ADHD diagnosis, min 6 of 9 questions that examine attention deficit
should have 2 or 3 scoring, min 6 of 9 questions that examine hyperactivity or impulsivity
should have 2 or 3 scoring. For ODD, min 4 of 8 questions should have 2 or 3 scoring; for BD
diagnosis, min 2 of 25 questions should exist for 6 months or 1 year. Confidence validity test
was conducted by Ercan et al. in Turkey [24].
4. Statistical evaluation
The statistics software SPSS 17.0 is utilized in this study. The data obtained through measure‐
ment is indicated as arithmetic mean (X) and standard deviation (SD); the data obtained
through census is indicated as percentages (%).The significance level in the evaluations is
determined as p<0.05. One- Sample Kolmogorov- Smirnov Test is used for control if variables
are normal distribution or not. The grading differences between the groups (children-
adolescents with ADHD diagnoses and healthy children-adolescents) are compared by using
the “Student t test” for the measuremental variables that conform to the normal distribution
and “Mann Whitney-U test” for the measuremental variables that do not conform to the normal
distribution. Tukey and Dunnett post hoc tests are also used for varyans analyze. Sperman
correlation test is used for showing correlations.
5. Results
Fourty two of patients who admitted into study were men (80.8%) and ten were women
(19.2%). The avarage age of children was 10.42 ±2.136. Control group was smilar to patient
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group in terms of avarage age and sex ratio. Socio- demographic characteristics of the group
with ADHD and the control group are shown in tables (Table 2 and table 3). Socio-demographic
differences between the two groups are outstanding.
Mean Standart deviation/Percent
Age 10,57 2,17
Mother age
Father Age
Education
The First 5 years
6th-10th.years
Number of siblings
2 and under 2
2- 4 siblings
36,03
40,44
n
32
20
n
46
3
5,87
6,16
%
61,5
38,5
%
93,9
6,1
Mother’s Educational level n %
Not education
Primary school
Secondary high school
High school
University
2
20
4
16
10
3,8
38,5
7,7
30,8
19,2
Father’sEducational level
Not education
Primary school
Secondary high school
High school
University
n
0
15
6
14
17
%
0
28,8
11,5
26,9
32,7
Location
Metropolitan
City
Town
Village
n
43
3
5
1
%
82,7
5,8
9,6
1,9
Monthly Income n %
Under 1000 TL
1000-3000 TL
4000-10000 TL
up to 10000
Father Occupation
18
27
6
1
n
34,6
51,9
11,5
1,9
%
Employee
Civil servant
Tradesman
16
11
3
30,8
21,2
5,8
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Mean Standart deviation/Percent
Retired
Other
Mother Occupation
Housewife
Civil servant
Nurse
Other
Psychopathology in family
Psychopathology in mother
Psychopathology in father
Psychopathology in siblings
5
17
n
41
6
2
3
n
3(ADHD,depression)
3(ADHD,depression ,psychotic disorder)
5(DEHB)
9,6
32,7
%
78,8
11,6
3,8
5,8
%
5,7
5,7
9,6
Table 2. Socio-demographic characteristics of the group with ADHD
Mean Standart deviation/Percent
Age 10,4 2,66
Mother age
Father Age
Education
The First 5 years
6th-10th.years
Number of siblings
2 and under 2
2- 4 siblings
37,7
41,8
n
15
10
n
22
3
5,28
6,79
%
60
40
%
88
12
Mother’s Educational level n %
Not education
Primary school
Secondary high school
High school
University
0
0
2
8
15
0
0
8
32
60
Father’sEducational level n %
Not education
Primary school
Secondary high school
High school
University
0
0
0
6
17
0
0
0
24
68
Location
Metropolitan
City
n
22
1
%
88
4
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Mean Standart deviation/Percent
Town
Village
2
0
8
0
Monthly Income n %
Under 1000 TL
1000-3000 TL
4000-10000 TL
up to 10000
Father Occupation
0
10
14
1
n
0
40
56
4
%
Employee
Civil servant
Tradesman
Retired
Other
2
4
4
1
9
8
16
16
4
36
Mother Occupation n %
Housewife
Civil servant
Nurse
Other
Psychopathology in family
Psychopathology in mother
Psychopathology in father
Psychopathology in siblings
12
7
6
0
n
0
0
0
48
28
24
0
%
0
0
0
Table 3. Socio-demographic characteristics of the control group
33 of patients (63.5%) were under long acting methylphenidate (OROS-MPH) therapy and 19
(36.5%) were under atomoxetine therapy. The medication use duration of first group was
18.54±15.43 months and second group was 18.3±14.8 months. No significant difference was
found between these two groups in terms of duration (p=0,958, t=0,52).
Dose rate for OROS-MPH was averagely 29,4±7,88 mg and for atomexetine was averagely
45,42±12,36 mg.
Height average in patient group was 141,4±13,8 cm, weight average was 37,07±11,17 kg and
height average for control group was 145,6±17,9cm, weight average was41,1±15,5 kg (p=0,251).
In terms of weight and height, there is no significant difference between atomexetine users,
MPH-OROS users and control group (Table 4 and 5).
When considered sub-group of life quality scale in patient group, phsycal sub-group was
found as 80,8 ±15,27, while emotianol sub-group was 66,05±18,26, life quality social was
76,15±22,28 and sub-group associated with school was 66,25±18,86. In control group, physcal
sub-group was found as 96,37±7,02, while emotional sub-group was 90,2±13,5, life quality
social 97,4±7,92 and sub-group associated with school was 91,6±10,19. There is significant
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difference between all fields of life quality in both groups (p<0.001*). When comparing life
quality of atomexetine and MPH users, no significant difference was found. But when
comparing long acting MPH users and atomexetine users with control group individually,
significant difference was examined in life quality sub-groups between control group and
other two groups (Table 4).
Patient group Control group Comparement of groups
Mean of ages 10,42 ±2,136 10,4±2,66 p= 0,970t= 0,041
Mean of height 141,63 ±14,19 145,6±17,9 p= 0,296t= 1,051
Mean of weight 37,07±11,17 41,12±15,5 p= 0,251t= 1,166
Mean of physical health field in
PedsQL 80,8 ±15,27 96,37±7,02
p< 0,001*
z= 4,845
Mean of emotional functioning
field in PedsQL 66,05±18,26 90,2±13,5
p< 0,001*
t= 5,867
Mean of , social functioning field in
PedsQL 76,15±22,28 97,4±7,92
p<0,001*
z=5,155
Mean of shcool functioning field in
PedsQL 66,25±18,86 91,6±10,19
P<0,001*
t= 7,668
(p<0,05*)
Table 4. Comparement of Socialdemographic datas and life quality
In OROS-MPH user group, while score between age and life quality in school field was found
significantly correlated; (p<0.05*, r=0.443) in atomexetine user group, no correlation was found.
When considering changes in hand-writing and drug use, 20 patients of 52 parents showed
recovery in hand writing after drug intake.
26 patients (50%) were applied before any other treatment of ADHD. However, several side
effects, and due to non compliance of previously treatment patients couldn’t maintain previous
treatment is observed. 16 patients of the 26 patients, (20.8%), inability to benefit from treatment,
2 patients (2.6%), insomnia, and 2 (2.6%), loss of appetite, and 2 (2.6%), nervousness, 1 'patients
(1.3%) hyperactivity, and 1 (1.3%), treatment noncompliance, and 1 (1.3%) increase in anxiety,
and 1 (1.3%) were somnolence. The relationship between these side effects, drugs, the treat‐
ment of patients do not benefit from atomoxetine before 4 out, 11 patients are used long-or
short-acting MPH, that 1 learned that used risperidone treatment. Insomnia, loss of appetite,
and nervousness side effects was seen with all the OROS MPH. Increase in hyperactivity and
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anxiety side effects could be showed with the use of OROS MPH. The side effects of somnolence
and non-compliance with the development of atomoxetine (Table 6).
Reason of finishing first treatment /
First treatment MPH Atomoxetine Risperidone
Non effective 11 4 1
Insomnia 2 - -
Loss of appetite 2 - -
Nervoussness 2 - -
Non compliance of treatment - 1 -
Hyperactivity 1 - -
Increase in anxiety 1 - -
Somnolence - 1 -
Table 6. Reason of finishing first treatment and relationship between drugs
Comparement of
patients under OROS-
MPH treatment with
atomoxetine treatment
Comparement of
patients under OROS-
MPH with control group
Comparement of
patients under
atomoxetine treatment
with control group
Mean of ages p= 0,586 p= 0,933 p= 0,806
Mean of height p= 0,294 p= 0,336 p= 1,00
Mean of weight p= 0,475 p= 0,225 p= 0,937
Mean of physical health field in
PedsQL
p= 0,991 p<0,001* p<0,005*
MMean of emotional functioning
field in PPedsQL
p= 1,00 p<0,001* p<0,001*
MMean of , social functioning field in
PedsQL
p= 0,821 p<0,001* p<0,005*
MMean of shcool functioning field in
PedsQL
p= 0,683 p<0,001* p<0,001*
(p<0,05*)
Table 5. Comparement of patients under OROS-MPH, atomoxetine treatment with each others and control group
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6. Discussion — conclusions
Life quality measurement is a method that gains gradually importance in children and
adolescent, mental health surveys and clinical practice. Investigators and practioners sup‐
posed that important deterioration in psychosocial fields associated with ADHD based on
basic symptoms of ADHD.
Children and adolescent with ADHD are at increased risk of academic failure, dropping out
of school or college, teenage pregnancy, alcohol and substance use and criminal behaviour.
Driving poses an additional risk. The emotional impairments of children and adolescents with
ADHD may include poor self-regulation of emotion, greater excessive emotional expression,
especially anger and aggression, greater problems coping with frustration, reduced empathy,
and decreased arousal to stimulation [25]. Children and adolescents with ADHD have
problems with peer relationships lack friendships, or have limitations in their activities with
friends if they do have friends. More than half of these children and adolescents have serious
problems with peer relationships [26]. Relationships and activities within the family can be
impaired and in some cases family relationships can break down, bringing additional social
and financial difficulties causing children to feel sad or show oppositional or aggressive
behavior [27].
Specific academic difficulties noted in children with ADHD include slower reading fluency
weaker reading comprehension (Ghelani and poor penmanship. Mastery of academic skills
can also be hampered by the secondary effects (impulsivity, inattention, and disorganization)
that ADHD can have upon a child’s ability to practice newly learned skills or study recently
presented material in the homework setting [28,29].
ADHD affects not only on the child, but also on parents and siblings, causing disturbances to
family and marital functioning, increased healthcare costs for patients and their family.
Children and their families changes from the preschool years to primary school and adoles‐
cence, with varying aspects of the disorder being more prominent at different stages. Also,
ADHD had more parent-reported problems in terms of emotional-behavioral role function,
behavior, mental health, and self-esteem. In addition, the problems of children with ADHD
had a significant impact on the parents' emotional health and parents' time to meet their own
needs, and they interfered with family activities and family cohesion[30].
ADHD is one of the most common psychiatric conditions estimated to affect 5-10% of all
children and ADHD predisposes children to impaired academic, familial, social, vocational
and emotional functioning if untreated. ADHD does not remit with the onset of puberty alone
and teenagers and adults continue to have symptoms of the disorder that cause significant
problems in their lives[31].
Children with attention-deficit and disruptive behavior disorder had, according to parent
ratings, a better emotional functioning score than children with anxiety disorders. Their
academic performance was significantly lower than for children with anxiety disorders and
other disorders, but school functioning was reported as equal. Clinicians reported more
problems in behavior toward others for this group compared to children with anxiety and
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mood disorders. Comorbidity of attention-deficit disorder or disruptive behavior disorder
with other psychiatric diagnoses did not influence overall Quality of Life. Also ıt had been
found that children with ADHD were more limited in schoolwork and social functioning[32].
Danckaerts M. et al. showed that a robust negative effect on QoL was reported by the parents
of children with ADHD across a broad range of psychopathology symptoms [33].
Because of difficulties in academical, social and emotional fields, the adverse effect of ADHD
on life quality is in evidence in current studies. Numerous studies have shown significant
recovery in life quality with medication use in case of ADHD [6,7,8]. The results of studies
carried out in this content showed adverse effect on all fields of children with ADHD diagnosis
and therapy requirement. Also, it is suggested that recovery attempts for children with ADHD
diagnosis should include all fields of life [34]. In line with previous studies, our study showed
that there is significantly difference in all sub-fields of life quality scale between control group
and under ADHD treatment [6,7,8]. Among this, when comparing all sub-fields of life quality
scale, there is no significant difference between atomexetine and OROS-MPH users. This result
is consistent with Leo Bastiaens’s study [35] conducted in 75 children between 6-12 age interval,
comparing the effects of atomexetine and stimulant therapy over life quality, and there are
further studies that suggests efficiency of OROS-MPH on life quality [36]. Also in another study
of Leo Bastiaens, 84 patients (atomoxetine n = 39/stimulants n = 45), between the ages of 5
and18, were treated for approximately 8 months. At end point, there were no significant
differences in improvements of quality of life between the two groups [37].
However an interesting study is that; 977 Male and female patients aged 6-17 years seeking
treatment for symptoms of ADHD were assessed,they were grouped according to wheth‐
er  they  were  prescribed  psycho-  and/or  pharmacotherapy  (treatment)  or  not  (no/‘other’
treatment)  Although  both  treatment  and  no/‘other’  treatment  cohorts  showed  improve‐
ments in mean Quality of Life over 12 months, the difference was small and not statistical‐
ly significant [38].
In our study, we found that confounding result, although patients with ADHD tent to show
a decrease in school success with increase in age, patients who take OROS-MPH treatment
show an increase in life quality school sub-score. This increase could be due to enhancement
in OROS-MPH usage dose with age. Higher dose levels in OROS-MPH could be asserted as
more effective for increase in academical success. Compared with the control group, decrease
of life quality sub-areas is supported the view of pharmacotherapy alone not enough. How‐
ever, further studies are needed to obtain certain data.
İn this point; V A Harpin showed that the primary school children with ADHD frequently
begins to be seen as being different as classmates start to develop the skills and maturity that
enable them to learn successfully in school. ADHD to succeed, more frequently the child
experiences academic failure, rejection by peers, and low self esteem. And This study sug‐
gested that assessment by an educational psychologist may help to unravel learning strengths
and difficulties, and advise on necessary support in the classroom [39].
50 children and adolescents with ADHD diagnosis, 30 control group and both of their parents
are examined. Rosenberg Self-Esteem Scale and Children’s Quality of Life Scale are used. The
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results of this study suggest that self-esteem in the children and adolescents with ADHD is
not significantly high and that their quality of life is significantly low. This is noticeable for it
draws attention to the psycho-social dimension in the clinical evaluation of the children with
ADHD [40]. İn this way, social support and motivational therapy may needed.
From anoher study Figure 1 shows benefit (dark green bars) or no benefit (light green bars) by
outcome group in treated participants with attention deficit hyperactivity disorder (ADHD)
versus untreated ADHD. Improvement was reported most often in studies of driving and
obesity outcomes (left side), with a greater proportion of outcomes reported to exhibit no
benefit following treatment compared with no treatment in studies of occupation (right side).
An intermediate proportion of studies of self-esteem, social function, academic, drug use/
addictive behavior,antisocial behavior, and services use outcomes reported benefit with
treatment [41].
İ
İ
 
0%
20%
40%
60%
80%
100%
No Benefit
Benefit
*This figure is taken from” A systematic review and analysis of long-term outcomes in attention deficit hyperactivity
disorder: effects of treatment and non-treatment “
Figure 1. Benefit and no benefit with treatment by outcome group
Treatment with OROS-MPH and atomoxsetine also have side effects. Evidence shows that
ADHD medications are safe and effective for children ages 6 and older. For children over
the age of 6, long-term effectiveness and adverse effects are not well studied. More studies
showed  that  psychostimulants  and  atomoxetine  may  cause  insomnia,  appetite  loss,
tiredness, social withdrawal, and abdominal pain. Psychostimulants and atomoxetine may
also cause a modest  increase in average blood pressure and average heart  rate in some
children and adolescents. Children or adolescents taking atomoxetine may be more likely
to think about suicide than children who do not take it. More adverse effects were report‐
ed in preschoolers than in elementary school children. Moodiness and irritability often led
to discontinuation of treatment with MPH. [42] In our study; 26 patients were applied before
any other treatment of ADHD. However, several side effects, and due to non compliance
of previously treatment patients couldn’t maintain previous treatment is observed. İnsom‐
nia, loss of appetite, nervousness, hyperactivity, increase in anxiety, and somnolence areside
effect which cause to stop first treatment. Insomnia, loss of appetite, and nervousness side
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effects was seen with all the OROS MPH. Increase in hyperactivity and anxiety side effects
could be showed with the use of OROS MPH. The side effects of somnolence and non-
compliance with the development of atomoxetine. But our datas are limited about relation‐
ship of side effects and life quality. Further studies are needed side effects of OROS-MPH
and atomoxetine on life quality.
Long-term effects of methylphenidate and atomoxsetine on growth rates of children with
ADHD are the other size of the treatment which also effect the Quality of life. The effect
of OROS-MPH and atomoxsetine over weight and height is  still  a  subject  of  discussion.
The final results, as to children with attention deficit who take stimulant medication grow
slower than children with no treatment, verify the results of previous studies in 1972-1973.
Recent study showed a decrease in expected weight and height growing in children who
take  stimulant  therapy.  In  treatments  continuing  2-3  years,  the  growing  speed  shows
normalization tendency [43,44].
İn the one of the review about effects of stimulants on height and weight; the quantitative
analyses showed that treatment with stimulant medication led to statistically significant delays
in height and weight. Treatment with stimulants in childhood reduced expected height and
weight. This review also found statistically significant evidence of attenuation of these deficits
over time. The qualitative review suggested that growth deficits may be dose dependent. Some
data suggest that ultimate adult growth parameters are not affected [45].
Prolonged medication (data evaluated at 6 months - 5 years) with short-acting MPH has shown
to have minimal impact on height only at the first 6 months; however, catch up growth was
detected during adolescent period in 96 cases wo were treated with short-acting MPH 0.41-0.49
mg/kg/day [46]. İn another research about the potential negative influence of methylphenidate
on growth; mean value of height was lower than expected mean height for age by 0.42 cm at
diagnosis. This difference increased to 2.69 cm (at 30 months of treatment), but it subsequently
decreased to 0.83 cm (at 48 months of treatment). The relationship between nutritional status
and the negative effects on the height curve in those patients would require nutritional
optimization to return anthropometric variables to normal [47].
Two new researches was performed on the effect of amoxetine on growing patients with 5
year follow-up and long- time efficiency and reliability of atomoxetine. After a 5 year follow-
up, it is suggested that while atomoxetine has no or a little effect on growing, in some cases
could cause reduction in growing. Especially in 18 months, growing could be affected a
little, however normal development could proceed in a period of 2-3 years [43,44]. Spenc‐
er et al present findings from an ongoing 5-year study of the efficacy and safety of treatment
with atomoxetine. After 1 month's treatment,they found patients weighed less than expected
from their starting percentiles relative to population norms, with a maximum shortfall at
15 months and a return to expected weight by 36 months. Patients were slightly shorter
than expected after 12 months, reaching a maximum shortfall at 18 months and returning
to expected height by 24 months. Patients in the top quartile for body mass index (BMI) or
weight at baseline, and those in the third quartile for height, showed 5-year decreases from
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expected  values.  Those  below  median  height  at  baseline  showed  increases  relative  to
expected values.[43]
In our study, we found no significant difference between both control group of OROS-MHP
and atomoxetine in terms of weight and height. And also no significant difference were
between treatment under OROS-MHP and atomoxetine. This result could be associated with
time limitation. Further studies are needed if there are difference effects of between OROS-
MPH and atomoxetine treatment on weight-height.
Although one of the research children with ADHD who performed poorly on the neuropsy‐
chological battery had greater BMI z-scores, and were more likely to be classified as over‐
weight/obese compared with children with ADHD who performed better on the
neuropsychological battery. In addition, children with ADHD who were taking a stimulant
medication had significantly lower BMI z-scores compared with children with ADHD who
were not taking medication or who were taking a non-stimulant medication. They claimed
that EF (Executive Function) is more impaired among children with ADHD and co-occurring
weight problems, highlighting the importance of self-regulation as a link between pediatric
obesity and ADHD [48].
An intresting point is that last studies reported an association between overweight and ADHD.
Although a higher prevalence of overweight/obesity was reported in clinical samples of
patients with ADHD, longitudinal studies are needed to better understand the mechanisms
underlying the association between ADHD and overweight/obesity [49].
Current data suggests an association between growing and medical effect of stimulants. Also
normal growing speeds have been shown in children who take no treatment with attention
deficit hyperactivity disorder. Therefore, further studies should focus on fields as detailed
definition of growing and development effects of stimulants in children with different ages,
determining the growing deficiency mechanism up to stimulant [50].
Gender differences is another variability that may affect the quality of life. Children with high
levels of ADHD symptoms have many associated behaviour problems, even in pre-school
years, and boys with high levels of ADHD symptoms are more severely affected compared
with girls. Datas of researches are not enough in this field.
Data from 5 clinical atomoxetine trials (4 from Europe and 1 from Canada) with similar
inclusion  and  exclusion  criteria  and  similar  durations  (8-  to  12-week  follow-up)  were
included in  the  pooled analysis.  136  girls  and 658 boys were  treated with atomoxetine.
Atomoxetine was effective in improving some aspects of health-related quality of life (HR-
QoL) in both genders without any significant differences across genders.Also, ıt was found
that correlations between core symptoms of ADHD and HR-QoL were low to moderate in
both boys and girls [51].
Also 6-17 aged of patients were treated with atomoxetine in two studies. ADHD-related
difficulties were assessed after 8 and 24 weeks using the Global Impression of Perceived
Difficulties (GIPD) instrument, which can be taken to reflect the patient's QoL from the three
perspectives. The GIPD scores over time suggest that patients' QoL, as reflected by perceived
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ADHD-related difficulties, improved with time on atomoxetine The sexes did not differ
significantly in mean GIPD total scores.and also improvement in ADHD-related difficulties
did not differ significantly between boys and girls [52]. In the second step of our study; we
aimed to compare effects of sex differences on response of treatment with both atomoxetine
and OROS-MPH, also correlation with life quality, ıt is our limitation of this study.
Consequently, ADHD, which is a chronic neuropsychiatric disorder, is known as negative‐
ly  effective  on life  quality  perception in  reports  about  children and it  is  suggested that
evaluation of  life  quality  in  follow-up and treatment  stages  of  ADHD and efficiency of
pharmacological treatment on life quality of this patients could be a guide for determin‐
ing  the  fields  that  children  have  difficulty  on.  Besides,  when  comparing  with  normal
population, the difficulties in academical, social and emotional fields could be seen more
frequently.  Medical treatment of attention deficit  and hyperactivity disorder alone could
cause  increasing  in  conseptualization  tendency  of  problems  and  nondevelopment  on
problem solving skills. Therefore, it is suggested that recovery attempts for children with
ADHD diagnosis should include all fields of life. Karabekiroğlu K. et al found that more
than half of the teachers denoted that the medication used for ADHD would have serious
side  effects  and  even  with  treatment  ADHD  would  not  sufficiently  improve,  and  the
children diagnosed with ADHD or autism should be trained at separate classes.  So that
the parents and teachers may benefit from structured educative programs inorder to get
rid of wrong assumptions and stigma [53].
One of the importent point is that further study is needed to understand the social and
psychological processes that underlie stigmatization, how parents balance perceived benefits
of treatment with mental health stigma concerns, and to determine how stigmatization effects
quality of life children with ADHD.
Although in our study, patients with ADHD tent to show a decrease in school success with
increase in age, patients who take OROS-MPH treatment show an increase in life quality school
sub-score. This information could be a guide for examining of detailed determining of OROS-
MPH effects.
Limitaton of our study are number of patients and time of treatments. Our datas are not enough
effects of socio-demographic differences, side effects, gender and stigma on life quality.
Measurement of quality of life in attention-deficit-hyperactivity disorder (ADHD) gives a more
complete picture of day-to-day functioning and treatment effects than behavioural rating
alone. Quality of life is effected from numerous factors so that new measurement parameters
should be developed.
In conclusion; there is significantly difference in all sub-fields of life quality scale between
control group and under ADHD treatment. Tretment is increase life quality of ADHD patients
but only medical treatment is not enought.There is no significant difference between weight
and height when comparing between control groups of OROS-MPH and atomexetine. Further
studies are needed to support the effects of OROS-MPH and atomoxetine on life quality and
weight-height.
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